Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy

Laboratory investigation

View More View Less
  • 1 Departments of Neurosurgery and
  • | 2 Biochemistry, Faculty of Medicine, Shimane University, Izumo, Shimane, Japan
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

Object

Indoleamine 2,3-dioxygenase (IDO), a kynurenine pathway (KP) enzyme catalyzing oxidation of the essential amino acid tryptophan (Trp), is thought to be involved in the immune resistance of malignant tumors through T-cell inactivation caused by Trp depletion and metabolite accumulation. Human malignant gliomas may use this strategy to escape immune attack. The object of this study was to investigate the possibility of IDO-dependent Trp depletion by malignant gliomas and the practicability of using an IDO inhibitor together with anticancer drugs to reserve Trp without decreasing the cytotoxicity of the drugs.

Methods

The authors studied expression of IDO and other KP enzymes and the effects of an IDO inhibitor, 1-methyl L-tryptophan (1MT), on Trp metabolism and cytotoxicity of anticancer drugs, together with direct measurement of KP metabolites, in cultured human malignant glioma cells.

Results

Upon interferon-γ (IFN-γ) stimulation, the glioma cells greatly increased their IDO mRNA expression concomitant with depletion of Trp. The IDO inhibitor 1MT successfully prevented Trp consumption by the stimulated glioma cells. Combining 1MT with anticancer drugs (temozolomide, bischloroethylnitrosourea [BCNU], etoposide and cisplatin) did not interfere with the drugs' suppression of growth of LN229 glioma cells but rather increased their inhibitory effects on IDO activity.

Conclusions

These findings suggest that the robust IDO expression with rapid consumption of Trp in human glioma cells induced by IFN-γ could lead to immune resistance in glioma cells. Indoleamine 2,3-dioxygenase inhibitors that prevent Trp depletion could be used with anticancer drugs to improve therapeutic effects.

Abbreviations used in this paper:

BCNU = bischloroethylnitrosourea; CDDP = cisplatin; FCS = fetal calf serum; IDO = indoleamine 2,3-dioxygenase; IFN = interferon; KP = kynurenine pathway; KYNase = kynureninase; LC/MS/MS = liquid chromatography–tandem mass spectrometry; PCR = polymerase chain reaction; Trp = tryptophan; 3HA = 3-hydroxyanthranilic acid; 3HK = 3-hydroxykynurenine.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1

    Bhardwaj N: Harnessing the immune system to treat cancer. J Clin Invest 117:11301136, 2007

  • 2

    Brandacher G, , Perathoner A, , Ladurner R, , Schneeberger S, , Obrist P, & Winkler C, et al.: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12:11441151, 2006

    • Search Google Scholar
    • Export Citation
  • 3

    Fallarino F, , Grohmann U, , You S, , McGrath BC, , Cavener DR, & Vacca C, et al.: The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:67526761, 2006

    • Search Google Scholar
    • Export Citation
  • 4

    Grant R, & Kapoor V: Inhibition of indoleamine 2,3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels. Biochem Pharmacol 66:10331036, 2003

    • Search Google Scholar
    • Export Citation
  • 5

    Grant RS, , Naif H, , Espinosa M, & Kapoor V: IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep 5:101104, 2000

    • Search Google Scholar
    • Export Citation
  • 6

    Heyes MP, , Chen CV, , Major EO, & Saito K: Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 326:351356, 1997

    • Search Google Scholar
    • Export Citation
  • 7

    Holladay FP, , Heitz T, & Wood GW: Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg 77:757762, 1992

    • Search Google Scholar
    • Export Citation
  • 8

    Hou DY, , Muller AJ, , Sharma MD, , DuHadaway J, , Banerjee T, & Johnson M, et al.: Inhibition of IDO in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with anti-tumor responses. Cancer Res 67:792801, 2007

    • Search Google Scholar
    • Export Citation
  • 9

    Huang A, , Fuchs D, , Widner B, , Glover C, , Henderson DC, & Allen-Mersh TG: Tryptophan decrease in advanced colorectal cancer correlates with immune activation and impaired quality of life. Br J Cancer 86:16911696, 2002

    • Search Google Scholar
    • Export Citation
  • 10

    Hwu P, , Du MX, , Lapointe R, , Do M, , Taylor MW, & Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:35963599, 2000

    • Search Google Scholar
    • Export Citation
  • 11

    Kwidzinski E, , Bunse J, , Aktas O, , Richter D, , Mutlu L, & Zipp F, et al.: Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 19:13471349, 2005

    • Search Google Scholar
    • Export Citation
  • 12

    Muller AJ, , DuHadaway JB, , Donover PS, , Sutanto-Ward E, & Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312319, 2005

    • Search Google Scholar
    • Export Citation
  • 13

    Munn DH, & Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:11471154, 2007

  • 14

    Munn DH, , Shafizadeh E, , Attwood JT, , Bondarev I, , Pashine A, & Mellor AL: Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:13631372, 1999

    • Search Google Scholar
    • Export Citation
  • 15

    Munn DH, , Sharma MD, , Baban B, , Harding HP, , Zhang Y, & Ron D: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22:633642, 2005

    • Search Google Scholar
    • Export Citation
  • 16

    Munn DH, , Zhou M, , Attwood JT, , Bondarev I, , Conway SJ, & Marshall B: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:11911193, 1998

    • Search Google Scholar
    • Export Citation
  • 17

    O'Connor JC, , Lawson MA, , Andre C, , Moreau M, , Lestage J, & Castanon N, et al.: Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry [epub ahead of print] 2008

    • Search Google Scholar
    • Export Citation
  • 18

    Sampson JH, , Archer GE, , Ashley DM, , Fuchs HE, , Hale LP, & Dranoff G: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci U S A 93:1039910404, 1996

    • Search Google Scholar
    • Export Citation
  • 19

    Schrocksnadel K, , Wirleitner B, , Winkler C, & Fuchs D: Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 364:8290, 2006

    • Search Google Scholar
    • Export Citation
  • 20

    Terness P, , Bauer TM, , Rose L, , Dufter C, , Watzlik A, & Simon H: Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196:447457, 2002

    • Search Google Scholar
    • Export Citation
  • 21

    Uyttenhove C, , Pilotte L, , Theate I, , Stroobant V, , Colau D, & Parmentier N: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:12691274, 2003

    • Search Google Scholar
    • Export Citation
  • 22

    Walker PR, , Calzascia T, , de Tribolet N, & Dietrich PY: T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 42:97122, 2003

    • Search Google Scholar
    • Export Citation
  • 23

    Walker PR, , Calzascia T, & Dietrich PY: All in the head: obstacles for immune rejection of brain tumours. Immunology 107:2838, 2002

  • 24

    Yamada K, , Miyazaki T, , Shibata T, , Hara N, & Tsuchiya M: Simultaneous measurement of tryptophan and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 867:5761, 2008

    • Search Google Scholar
    • Export Citation
  • 25

    Yang L, , Ng KY, & Lillehei KO: Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10:138147, 2003

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 688 178 22
Full Text Views 208 30 6
PDF Downloads 168 34 5
EPUB Downloads 0 0 0